Drugs Affecting Lipid Metabolism: Risk Factors and Future Directions

Gotto, A.M.; Paoletti, R.; Smith L.C.; Catapano, A.L.; Jackson, A.S. (edited by)

ISBN 10: 0792341678 / ISBN 13: 9780792341673

Published by Kluwer Academic Publishers, The Netherlands, 1996

About this Item

Pages are clean and tight throughout. Previous owner's signature on FEP. Contains several charts and graphs. There is a minor scratch to the front cover.

Seller Inventory # 169206

Bibliographic Details

• Title: Drugs Affecting Lipid Metabolism: Risk Factors and Future Directions
• Publisher: Kluwer Academic Publishers, The Netherlands
• Publication Date: 1996
• Language: English
• ISBN 10: 0792341678
• ISBN 13: 9780792341673
• Binding: Hardcover
• Condition: Very Good
• Dust Jacket Condition: No Dust Jacket
• Seller catalogs:
  • Drugs/Alcohol/Pharmacology

About this title

Synopsis

Even a brief scan of the table of contents of the present volume is enough to disclose the diversity of research interests and opinions in the field of lipidology. It is precisely this diversity that is the strength of our field and that was showcased by the XII International Symposium of DRUGS AFFECTING LIPID METABOLISM (DALM). The papers published here from these proceedings may be divided into three categories: those that define-and refine---our understanding ofthe clinical benefit of aggressive lipid management, those that develop our knowledge of ris!. assessment, and those that discuss the genetic, bio~hemical, and biophysical mechanisms underlying the pathology of coronary heart disease. On the clinical front, further analysis of the results of the Scandinavian Simvastatin Survival Study (4S) has indicated the cost-effectiveness of therapy in patients with established coronary heart disease. The West of Scotland Coronary Prevention Study (WOSCOPS), whose methodology was described at the DALM XII symposium, has demonstrated in a mostly primary-prevention population what 4S demonstrated for secondary prevention the year before: aggressive lipid-regulating therapy reduces coronary heart disease morbidity and mortality rates without concurrently increasing mortality from noncardiovascular causes. In the future, important considerations will be to develop protocols that maximize benefit in groups underrepresented in traditional clinical research­ for example, women and the elderly-and to improve compliance to existing treatment regimens. Furthermore, antioxidant, omega-3 fatty acid, and gene therapies warrant further investigation.